The difference between cytarabine and Quizartinib and analysis of combination treatment options

Cytarabine (Cytarabine) and Quizartinib (Quizartinib) are two anti-tumor drugs with different mechanisms of action. They are commonly used in the treatment of acute myeloid leukemia (AML). With the development of precision medicine and targeted therapy, the combination of the two has been included in more and more clinical studies, especially for AML patients carrying FLT3-ITD mutations. This article will conduct a detailed analysis of the basic characteristics, mechanism of action, clinical indications, combined treatment options, advantages and precautions of the two drugs.

1. Basic characteristics and pharmacological mechanisms of cytarabine and quizartinib

Cytarabine is a classic chemotherapy drug and an antimetabolite cytotoxic drug. Its main mechanism is through the incorporation of metabolites into DNA chains, inhibiting DNA synthesis and repair, thereby interfering with the replication and proliferation of cancer cells. As the "cornerstone drug" in the treatment of AML, cytarabine is widely used to induce remission and consolidate treatment, and is often combined with anthracyclines (such as daunorubicin) to form the "7+3 regimen".

Quizatinib is a new type of targeted drug that specifically inhibits the FLT3 receptor tyrosine kinase, especially the FLT3-ITD mutation, which is a poor prognosis mutation found in approximately 30% of AML patients. FLT3-ITDactivates a variety of downstream signaling pathways, such as PI3K/AKT, MAPK, etc., leading to abnormal proliferation of leukemia cells and inhibition of apoptosis. Quizartinib effectively inhibits abnormal signaling and induces leukemia cell death by targeting this mutation site.

Therefore, cytarabine mainly relies on broad-spectrum cytotoxicity, while quizartinib relies on precise intervention targeting FLT3, and the two mechanisms of action are complementary.

2. Differences in indications and treatment purposes between cytarabine and quizartinib

Cytarabine is an important part of the standard treatment of AML and is suitable for many types of AML patients, especially during the induction phase and consolidation treatment phase. Its indications are not affected by molecular mutations and have a wide range of applications. However, side effects during treatment are relatively large, such as bone marrow suppression, infection, liver and kidney function damage, etc.

The use of quizartinib is more precise and is specifically used for patients with relapsed or refractory AML with FLT3-ITD mutations. Because FLT3-ITD mutations are often associated with higher white blood cell counts, rapid disease progression, and short survival, quizartinib can significantly improve prognosis in specific populations. The drug has been approved for marketing in some countries, but it has not been officially approved in mainland China and needs to be obtained through overseas channels.

Clinically, although quizartinib alone is effective, it is prone to drug resistance or relapse. Therefore, it is more often designed as a combination drug regimen, especially in combination with chemotherapy drugs such as cytarabine to enhance the anti-leukemia effect.

3. Research on combined treatment options and their efficacy

The combination treatment regimen of cytarabine and quizartinib is mainly found in studies on patients with FLT3 mutationsAML. Typical solutions include:

1.Induction phase treatment: low-dose or medium-dose cytarabine + quizartinib. Cytarabine is used to eliminate rapidly dividing leukemia cells, while quizartinib precisely inhibits the FLT3 signal and collaboratively kills the remaining mutated cells.

2.Consolidation phase treatment: medium-dose cytarabine combined with quizartinib continues to consolidate the efficacy and reduce minimal residual disease (MRD).

3.Maintenance treatment: Some patients can continue to use quizartinib single-agent maintenance after remission to delay recurrence.

In a project called QuANTUM-First In 's 3 clinical study, quizartinib combined with standard induction / consolidation chemotherapy regimen (containing cytarabine) significantly prolonged FLT3-I Overall survival (OS) and event-free survival (EFS) of TDpositiveAML patients. Compared with the traditional "7+3 regimen", this combination regimen has a higher complete remission rate and lower relapse rate, and some patients have successfully entered the autologous or allogeneic hematopoietic stem cell transplantation procedure.

In addition, for patients who are elderly or in poor health and cannot tolerate high-intensity chemotherapy, there are also studies exploring the combination of low-dose cytarabine and quizartinib, which has achieved a certain remission effect and provided a new treatment option for high-risk groups.

4. Advantages and Risk Considerations of Combination Medication

Advantages:

1. Targeted precision superimposes traditional cytotoxic treatment: cytarabine is responsible for broad-spectrum killing, and quizartinib provides mutation site inhibition. The two complement each other and improve the remission rate.

2.Prolong survival time: Combination therapy has shown a significant prolongation of survival time in multiple clinical studies.

3. Promote entry into the transplant window: By quickly relieving the disease, combined treatment can help more patients successfully enter the transplant stage.

4.Adaptable to patients with different physical constitutions: The dosage of cytarabine can be flexibly adjusted, and is suitable for elderly or patients with comorbidities.

Risks and Challenges:

1. Enhanced bone marrow suppression: Both drugs have hematopoietic inhibitory effects, and combined use may aggravate leukopenia and infection risks.

2.Resistance issues: Long-term use of quizartinib may still cause resistance mutations (such asFLT3-TKD), which requires close monitoring.

3.Drug interactions: Quizartinib is a CYP3A4 substrate and may interact with antifungals and certain chemotherapy drugs, requiring strict pharmacokinetic management.

4. Access restrictions: Quizartinib has not yet been launched in China and needs to be imported through formal foreign channels. The price is relatively high and it is not covered by medical insurance.

The combination treatment of cytarabine and quizartinib represents the combination of traditional chemotherapy and targeted therapy, bringing new treatment opportunities to patients with FLT3 mutationsAML. The synergistic effect of the two is expected to break through the treatment bottleneck of relapsed and refractory AML. In the future, as quizartinib becomes available in more countries and its price gradually decreases, this combination model is expected to become part of the standard treatment plan. Both efficacy and safety should be taken into consideration during treatment, and the medication regimen should be adjusted individually to achieve maximum therapeutic benefit.

Reference materials:https://www.drugs.com/